Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00042471 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Bioavailability of Pramlintide
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT00042471 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 75 participants.
The verdict
NCT00042471, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
This is a randomized, open-label, crossover study to examine the bioavailability of pramlintide in normal weight and overweight subjects with type 1 and type 2 diabetes mellitus using insulin.
Interventions
- DRUG Pramlintide acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2002-06 |
| Est. Completion | 2002-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00042471
The ClinicalTrials.gov registry entry for NCT00042471 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pramlintide acetate is the first listed.
NCT00042471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00042471 about?
NCT00042471 is a clinical study titled "Evaluation of the Bioavailability of Pramlintide". This is a randomized, open-label, crossover study to examine the bioavailability of pramlintide in normal weight and overweight subjects with type 1 and type 2 diabetes mellitus using insulin.
What is the current status of trial NCT00042471?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2002-06. Estimated completion is 2002-12.
What interventions are being tested in trial NCT00042471?
The interventions under investigation include: Pramlintide acetate (DRUG).
Who is sponsoring clinical trial NCT00042471?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.